

**MVP List of Drugs with Largest Net Price Increase Impact**  
**Pursuant to 18 V.S.A. § 4635(b)(1)(C)(i)**  
**2023 to 2022**

Ranking	National Drug Code(s) (NDC)	Drug Name	Manufacturer	Brand/ Generic	Specialty?	1 Year % Increase
1	00002144511	TALTZ INJ 80MG/ML	LILLY	Brand	YES	96.8%
2	66215061606	UPTRAVI TAB 1600MCG	ACTELION PHARMACEUTICALS	Brand	YES	115.6%
3	00003218851	ORENCIA CLCK INJ 125MG/ML	B-M SQUIBB U.S. (PRIMARY CARE)	Brand	YES	55.7%
4	64406001101	PLEGRIDY INJ PEN	BIOGEN IDEC	Brand	YES	34.4%
5	57894064011	TREMFYA INJ 100MG/ML	JANSSEN BIOTECH	Brand	YES	21.8%
6	44087334401	REBIF REBIDO INJ 44/0.5	SERONO	Brand	YES	54.2%
7	00169452514	WEGOVY (4) INJ 0.25MG	NOVO NORDISK	Brand	NO	29.6%
8	00002149580	MOUNJARO (4) PEN 5/0.5	LILLY	Brand	NO	33.1%
9	00032122401	CREON CAP 24000UNT	ABBVIE	Brand	NO	97.6%
10	00003218811	ORENCIA INJ 125MG/ML	B-M SQUIBB U.S. (PRIMARY CARE)	Brand	YES	38.4%

Note: Price increases were calculated after applying any manufacturer rebates and administrative fees.

Note: No generic NDCs have increased 15% over the previous calendar year or alternatively, 50% or more over the past 5 years.